Bleeding avoidance strategies in percutaneous coronary intervention
- PMID: 34426673
- DOI: 10.1038/s41569-021-00598-1
Bleeding avoidance strategies in percutaneous coronary intervention
Abstract
For many years, bleeding has been perceived as an unavoidable consequence of strategies aimed at reducing thrombotic complications in patients undergoing percutaneous coronary intervention (PCI). However, the paradigm has now shifted towards bleeding being recognized as a prognostically unfavourable event to the same extent as having a new or recurrent ischaemic or thrombotic complication. As such, in parallel with progress in device and drug development for PCI, there is clinical interest in developing strategies that maximize not only the efficacy but also the safety (for example, by minimizing bleeding) of any antithrombotic treatment or procedural aspect before, during or after PCI. In this Review, we discuss contemporary data and aspects of bleeding avoidance strategies in PCI, including risk stratification, timing of revascularization, pretreatment with antiplatelet agents, selection of vascular access, choice of coronary stents and antithrombotic treatment regimens.
© 2021. Springer Nature Limited.
References
-
- Capodanno, D., Alfonso, F., Levine, G. N., Valgimigli, M. & Angiolillo, D. J. ACC/AHA versus ESC Guidelines on dual antiplatelet therapy. J. Am. Coll. Cardiol. 72, 2915–2931 (2018). - PubMed
-
- Capodanno, D. et al. Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nat. Rev. Cardiol. 17, 242–257 (2020). - PubMed
-
- Knuuti, J. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur. Heart J. 41, 407–477 (2020). - PubMed
-
- Costa, F. et al. Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting. J. Am. Coll. Cardiol. 73, 741–754 (2019). - PubMed
-
- Valgimigli, M. et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur. Heart J. 38, 804–810 (2017). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
